Abstract 3986: Novel LIPA targeted therapy for treating ovarian cancer
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-3986
Abstract: BACKGROUND: Ovarian cancer (OCa) is the deadliest of all gynecologic cancers in the United States. Currently approved therapies have improved OCa survival for clinically localized disease, however, the majority (~90%) of patients with high-grade serous… read more here.
Keywords: cell; ovarian cancer; lipa; oca ... See more keywords
Abstract 4813: ERX-208 as a novel therapeutic for treating ovarian cancer by enhancing endoplasmic reticulum stress
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4813
Abstract: Background: Ovarian cancer (OCa) is the deadliest of all gynecologic cancers in the United States. Despite initial response to chemotherapy, most OCa patients become chemo resistant and progress to metastatic disease. Here, we tested the… read more here.
Keywords: erx 208; oca; ovarian cancer; oca cells ... See more keywords
GATA1-induced upregulation of LINC01503 promotes carboplatin resistance in ovarian carcinoma by upregulating PD-L1 via sponging miR-766-5p
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Ovarian Research"
DOI: 10.1186/s13048-021-00856-3
Abstract: Background Ovarian Carcinoma (OCa) is a high-mortality malignancy derived from female reproductive system. Increasing evidence has identified long non-coding RNAs (lncRNAs) as important regulators in OCa chemoresistance. In this study, we intended to explore the… read more here.
Keywords: cbp; oca cells; resistance; mir 766 ... See more keywords